Suppressive Effects of TNF-alpha, TGF-beta1, and Chemokines on Megakaryocytic Colony Formation in CD34<sup>+</sup>Cells Derived from Umbilical Cord Blood Compared with Mobilized Peripheral Blood and Bone Marrow

Lü, Li; Wang, Lisheng; Cooper, Ryan; Liu, Hong Jun; Turner, Katherine J.; Weich, Nadine; Broxmeyer, Hal E.

doi:10.1089/152581600319405

Cited by 11 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human promyelocytic leukemia cells (HL-60), both inhibit cell growth, which is associated with down-regulation of c-myc expression (40). In hematopoietic stem cells, hematopoietic progenitor cells and cord blood megakaryocytes (MK), TNF-a and TGF-b can inhibit cell proliferation and colony-forming ability (41,42). It has also been found that in mouse hepatocytes, TGF-b1 can inhibit the production of hepatic growth factor (HGF), while TNF-a is positively correlated with the production of TGF-b, and inhibiting the level of TNF-a can inhibit the production of TGF-b1, thereby enhancing liver tissue regeneration (43).…”

Section: Role Of Tnf-a and Tgf-b In Cell Proliferationmentioning

confidence: 99%

Duality of Interactions Between TGF-β and TNF-α During Tumor Formation

Liu

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment is essential for the formation and development of tumors. Cytokines in the microenvironment may affect the growth, metastasis and prognosis of tumors, and play different roles in different stages of tumors, of which transforming growth factor β (TGF-β) and tumor necrosis factor α (TNF-α) are critical. The two have synergistic and antagonistic effect on tumor regulation. The inhibition of TGF-β can promote the formation rate of tumor, while TGF-β can promote the malignancy of tumor. TNF-α was initially determined to be a natural immune serum mediator that can induce tumor hemorrhagic necrosis, it has a wide range of biological activities and can be used clinically as a target to immune diseases as well as tumors. However, there are few reports on the interaction between the two in the tumor microenvironment. This paper combs the biological effect of the two in different aspects of different tumors. We summarized the changes and clinical medication rules of the two in different tissue cells, hoping to provide a new idea for the clinical application of the two cytokines.

show abstract

Section: Role Of Tnf-a and Tgf-b In Cell Proliferationmentioning

confidence: 99%

Duality of Interactions Between TGF-β and TNF-α During Tumor Formation

Liu

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…It is well established that T cell responses are crucial for clearing viral-infected cells and controlling viral replication. T cell responses are beneficial to host immune defense against HIV infection [ 32 , 33 ], and CD4 + T cell responses are critical for humoral responses. We evaluated the T cell responses (Ag-specific Th1- and Th2 associated cytokine induction) induced by various VLPs.…”

Section: Discussionmentioning

confidence: 99%

Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses

Sun

Zhang

et al. 2017

Virol J

View full text Add to dashboard Cite

BackgroundInduction of broad immune responses at mucosal site remains a primary goal for most vaccines against mucosal pathogens. Abundance of evidence indicates that the co-delivery of mucosal adjuvants, including cytokines, is necessary to induce effective mucosal immunity. In the present study, we set out to evaluate the role of a chemokine, CCL20, as an effective mucosal adjuvant for HIV vaccine.MethodsTo evaluate the role of CCL20 as a potent adjuvant for HIV vaccine, we examined its effects on antigen-specific antibody responses, level of antibody-secreting cells, cytokine production and intestinal homing of plasma cells in vaccine immunized mice.ResultsCCL20-incorporated VLP administered by mucosal route (intranasal (n = 10, p = 0.0085) or intravaginal (n = 10, p = 0.0091)) showed much higher potency in inducing Env-specific IgA antibody response than those administered by intramuscular route (n = 10). For intranasal administration, the HIV Env-specific IFN-γ(751 pg/ml), IL-4 (566 pg/ml), IL-5 (811 pg/ml) production and IgA-secreting plasma cells (62 IgA-secreting plasma cells/106 cells) in mucosal lamina propria were significantly augmented in CCL20-incorporated VLP immunized mice as compared to those immunized with Env only VLPs (p = 0.0332, 0.0398, 0.033, 0.0302 for IFN-γ, IL-4, IL-5, and IgA-secreting plasma cells, respectively).Further, anti-CCL20 mAb partially suppressed homing of Env-specific IgA ASCs into small intestine in mice immunized with CCL20-incorporated VLP by intranasal (62 decreased to 16 IgA- secreting plasma cells/106 cells, p = 0.0341) or intravaginal (52 decreased to 13 IgA- secreting plasma cells/106 cells, p = 0.0332) routes.ConclusionOur data indicated that the VLP-incorporated CCL20 can enhance HIV Env-specific immune responses in mice, especially those occurring in the mucosal sites. We also found that i.m. prime followed by mucosal boost is critical and required for CCL20 to exert its full function as an effective mucosal adjuvant. Therefore, co-incorporation of CCL20 into Env VLPs when combined with mucosal administration could represent a novel and promising HIV vaccine candidate.

show abstract